Novel Drug Shows Promise for Hidradenitis Suppurativa

SAN DIEGO — The investigative oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib shows promise in patients with moderate to severe hidradenitis suppurativa (HS), results from a randomized 16-week phase 2 trial showed. “Research shows that the TNF-alpha and IL-17 signaling pathways have important roles in HS,” lead investigator Alexa B... 
Get In Touch

Cape Breton, NS

+012 345 67890

Follow Us
Flickr Photos

Copyright © 2023 Toady's News. All Rights Reserved